IL17A and cancer: This study has uncovered a hitherto unknown mechanism involving the induction of mesenchymal reprogramming by the synergistic action of IL‐17A and TNF produced by Th17 cells, which renders the mesothelial monolayer susceptible to cancer cell adhesion.